These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11757700)

  • 1. 6. Report on workshop: EBMT workshop "High dose therapy in aggressive NHL".
    Schmitz N
    Ann Hematol; 2001; 80 Suppl 3():B24-5. PubMed ID: 11757700
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic strategies for aggressive lymphomas: the trials of the DSHNHL.
    Schmits R; Glass B; Trümper L; Pfreundschuh M;
    Ann Hematol; 2001; 80 Suppl 3():B77-83. PubMed ID: 11757714
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment strategies in elderly patients with aggressive histology lymphoma.
    Kouroukis CT; Meyer RM
    Ann Hematol; 2001; 80 Suppl 3():B86-8. PubMed ID: 11757717
    [No Abstract]   [Full Text] [Related]  

  • 4. 4. Report on workshop: UICC workshop "Therapy of NHL in early stages". Part 2: Aggressive lymphomas.
    Schmits R; Trümper L
    Ann Hematol; 2001; 80 Suppl 3():B16-9. PubMed ID: 11757698
    [No Abstract]   [Full Text] [Related]  

  • 5. Indications for early autologous stem cell transplantation in aggressive lymphoma.
    Kluin-Nelemans HC
    Ann Hematol; 2001; 80 Suppl 3():B121-2. PubMed ID: 11757692
    [No Abstract]   [Full Text] [Related]  

  • 6. Aggressive lymphoma: improving treatment outcome with rituximab.
    Coiffier B; Pfreundschuh M; Stahel R; Vose J; Zinzani PL
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S43-50. PubMed ID: 12710590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [High-dose chemotherapy with bone marrow transplantation in recurrent or refractory NHL].
    Torello E; Koziner B
    Sangre (Barc); 1993 Dec; 38(6):473-80. PubMed ID: 7909622
    [No Abstract]   [Full Text] [Related]  

  • 8. Dose intensity or monoclonal antibody in first-line treatment.
    Coiffier B
    Hematol J; 2004; 5 Suppl 3():S154-8. PubMed ID: 15190299
    [No Abstract]   [Full Text] [Related]  

  • 9. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma.
    Ladetto M; Zallio F; Vallet S; Ricca I; Cuttica A; Caracciolo D; Corradini P; Astolfi M; Sametti S; Volpato F; Bondesan P; Vitolo U; Boccadoro M; Pileri A; Gianni AM; Tarella C
    Leukemia; 2001 Dec; 15(12):1941-9. PubMed ID: 11753616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of monoclonal antibody therapy with conventional and high-dose treatment: current clinical trials.
    Horning JS
    Semin Hematol; 2000 Oct; 37(4 Suppl 7):27-33. PubMed ID: 11147487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Hodgkin lymphoma: an update.
    Hennessy BT; Hanrahan EO; Daly PA
    Lancet Oncol; 2004 Jun; 5(6):341-53. PubMed ID: 15172354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies in lymphoid neoplasia: principles for optimal combined therapy.
    Maloney GD
    Semin Hematol; 2000 Oct; 37(4 Suppl 7):17-26. PubMed ID: 11147485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments.
    Tarella C; Cuttica A; Caracciolo D; Zallio F; Ricca I; Bergui L; Gavarotti P; Marinone C; Pagano M; Rossi G; de Crescenzo A; Salomone A; Ladetto M; Boccadoro M; Pileri A
    Ann Hematol; 2001; 80 Suppl 3():B123-6. PubMed ID: 11757693
    [No Abstract]   [Full Text] [Related]  

  • 14. Innovative strategies in lymphoma therapy.
    Jäger U
    Wien Klin Wochenschr; 2003 Aug; 115(13-14):462-70. PubMed ID: 13677264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in indolent lymphomas.
    Sousou T; Friedberg J
    Semin Hematol; 2010 Apr; 47(2):133-42. PubMed ID: 20350660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    White CA
    Curr Pharm Biotechnol; 2003 Aug; 4(4):221-38. PubMed ID: 14529425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab and dose dense chemotherapy in primary breast lymphoma.
    Avilés A; Castañeda C; Neri N; Cleto S; Nambo MJ
    Haematologica; 2007 Aug; 92(8):1147-8. PubMed ID: 17650450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.
    Tsai D; Moore H; Hardy C; Porter D; Loh E; Vaughn D; Luger S; Schuster S; Stadtmauer E
    Bone Marrow Transplant; 1999 Sep; 24(5):521-6. PubMed ID: 10482937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma.
    Micallef IN; Kirk A; Norton A; Foran JM; Rohatiner AZ; Lister TA
    Blood; 1999 Apr; 93(7):2427-8. PubMed ID: 10215354
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.